These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10549572)

  • 1. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
    Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
    Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity.
    Woo BH; Lee JT; Lee KC
    Arch Pharm Res; 1994 Dec; 17(6):452-7. PubMed ID: 10319157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural features of the antibody-A chain linkage that influence the activity and stability of ricin A chain immunotoxins.
    Cumber AJ; Westwood JH; Henry RV; Parnell GD; Coles BF; Wawrzynczak EJ
    Bioconjug Chem; 1992; 3(5):397-401. PubMed ID: 1329989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
    Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolane.
    Carroll SF; Bernhard SL; Goff DA; Bauer RJ; Leach W; Kung AH
    Bioconjug Chem; 1994; 5(3):248-56. PubMed ID: 7918744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
    Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
    Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
    Vallera DA; Burns LJ; Frankel AE; Sicheneder AR; Gunther R; Gajl-Peczalska K; Pennell CA; Kersey JH
    J Immunol Methods; 1996 Oct; 197(1-2):69-83. PubMed ID: 8890895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG; Marks JW; Cheung LH
    Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sepharose-unbinding ricin E as a source for ricin A chain immunotoxin.
    Woo BH; Lee JT; Na DH; Lee KC
    J Immunol Methods; 2001 Mar; 249(1-2):91-8. PubMed ID: 11226467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
    Kornfeld SB; Leonard JE; Mullen MD; Taetle R
    Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced stability of an immunotoxin made with abrin A chain and a hindered disulphide cross-linker.
    Cumber A; Wawrzynczak E
    Biochem Soc Trans; 1992 Nov; 20(4):312S. PubMed ID: 1486982
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
    Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
    Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of fresh leukemic cells to T101 ricin A-chain immunotoxin: a comparative study between Fab fragment and whole Ig conjugates.
    Chiron M; Derocq JM; Kuhlein E; Roubinet F; Demur C; Grandjean H; Huguet F; Jaffrezou JP; Jansen F; Laurent G
    Leuk Res; 1989; 13(6):491-9. PubMed ID: 2788783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of antibody responses to ricin A chain (RTA) by monoclonal anti-RTA antibodies.
    Byers VS; Austin EB; Clegg JA; Denton G; Gunn B; Hooi D; Hudecz F; Price MR; Baldwin RW
    J Clin Immunol; 1993 Nov; 13(6):406-14. PubMed ID: 7507127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
    Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
    J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
    Fulton RJ; Uhr JW; Vitetta ES
    J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
    Pietersz GA; Kanellos J; McKenzie IF
    Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.